Last reviewed · How we verify
Risk of symptomatic peptic ulcer — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Risk of symptomatic peptic ulcer (Risk of symptomatic peptic ulcer) — AstraZeneca.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Risk of symptomatic peptic ulcer TARGET | Risk of symptomatic peptic ulcer | AstraZeneca | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Risk of symptomatic peptic ulcer CI watch — RSS
- Risk of symptomatic peptic ulcer CI watch — Atom
- Risk of symptomatic peptic ulcer CI watch — JSON
- Risk of symptomatic peptic ulcer alone — RSS
Cite this brief
Drug Landscape (2026). Risk of symptomatic peptic ulcer — Competitive Intelligence Brief. https://druglandscape.com/ci/risk-of-symptomatic-peptic-ulcer. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab